Search
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalThe goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer. … Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC).
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigationalVericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. … [A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated
Products: VERQUVO 2,5 MG FİLM KAPLI TABLET , 14 ADET, VERQUVO 5 MG FİLM KAPLI TABLET , 14 ADETPrimidone
go.drugbank.com/drugs/DB00794ApprovedVet approved[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]
Categories: combinations of barbituratesProducts: Mysoline 250 mg Tabletten, PRIMIDONA 250 MG TABLETASVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalIt consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions … [L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigationalThe absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]
Products: CIMZIA 200 MG, CIMZIA 200 MG ILO IN FERTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalThe cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. … Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.
Products: Enhertu 100 mg IV İnfüzyonluk Çözelti Hazırlamada Kullanılacak Konsantre İçin Toz, 1 ADETTerpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawndata to establish general recognition of the safety and effectiveness of these ingredients". … Elixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies.
Thimerosal
go.drugbank.com/drugs/DB11590ApprovedThiomersal (INN), commonly known in the U.S. as thimerosal, is an organomercury compound. This compound is a well-established and widely used antiseptic and antifungal agent. Developed in 1927, thimerosal has been and is still being used...
Synonyms: [(o-carboxyphenyl)thio]ethylmercury sodium salt, o-(ethylmercurithio)benzoic acid sodium saltCategories: Compounds used in a research, industrial, or household settingVibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigationalTwo serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. … _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1.
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalin the context of resistant cancers. … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]